324 related articles for article (PubMed ID: 36522653)
1. Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer.
Lo A; McSharry M; Berger AH
BMC Cancer; 2022 Dec; 22(1):1315. PubMed ID: 36522653
[TBL] [Abstract][Full Text] [Related]
2. Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.
Ricciuti B; Son J; Okoro JJ; Mira A; Patrucco E; Eum Y; Wang X; Paranal R; Wang H; Lin M; Haikala HM; Li J; Xu Y; Alessi JV; Chhoeu C; Redig AJ; Köhler J; Dholakia KH; Chen Y; Richard E; Nokin MJ; Santamaria D; Gokhale PC; Awad MM; Jänne PA; Ambrogio C
Clin Cancer Res; 2022 Apr; 28(8):1640-1650. PubMed ID: 35091439
[TBL] [Abstract][Full Text] [Related]
3. Multiomic characterization of oncogenic signaling mediated by wild-type and mutant RIT1.
Lo A; Holmes K; Kamlapurkar S; Mundt F; Moorthi S; Fung I; Fereshetian S; Watson J; Carr SA; Mertins P; Berger AH
Sci Signal; 2021 Nov; 14(711):eabc4520. PubMed ID: 34846918
[TBL] [Abstract][Full Text] [Related]
4. KRAS
Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
[TBL] [Abstract][Full Text] [Related]
5. Label-free quantitative proteomics and N-glycoproteomics analysis of KRAS-activated human bronchial epithelial cells.
Sudhir PR; Chen CH; Pavana Kumari M; Wang MJ; Tsou CC; Sung TY; Chen JY; Chen CH
Mol Cell Proteomics; 2012 Oct; 11(10):901-15. PubMed ID: 22761399
[TBL] [Abstract][Full Text] [Related]
6. In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells.
Riffo-Campos ÁL; Castillo J; Vallet-Sánchez A; Ayala G; Cervantes A; López-Rodas G; Franco L
Oncol Rep; 2016 Dec; 36(6):3627-3634. PubMed ID: 27805251
[TBL] [Abstract][Full Text] [Related]
7. Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer.
de Miguel FJ; Sharma RD; Pajares MJ; Montuenga LM; Rubio A; Pio R
Cancer Res; 2014 Feb; 74(4):1105-15. PubMed ID: 24371231
[TBL] [Abstract][Full Text] [Related]
8. Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells.
Kumazaki M; Shimomura I; Kiyono T; Ochiya T; Yamamoto Y
Biochem Biophys Res Commun; 2020 Apr; 525(2):483-490. PubMed ID: 32111352
[TBL] [Abstract][Full Text] [Related]
9. KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform.
Salmón M; Paniagua G; Lechuga CG; Fernández-García F; Zarzuela E; Álvarez-Díaz R; Musteanu M; Guerra C; Caleiras E; Muñoz J; Ortega S; Drosten M; Barbacid M
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301865
[TBL] [Abstract][Full Text] [Related]
10. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
[TBL] [Abstract][Full Text] [Related]
11. YTHDF1 Promotes Cyclin B1 Translation through m
Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
[TBL] [Abstract][Full Text] [Related]
12. AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicing.
Laliotis GI; Chavdoula E; Paraskevopoulou MD; Kaba A; La Ferlita A; Singh S; Anastas V; Nair KA; Orlacchio A; Taraslia V; Vlachos I; Capece M; Hatzigeorgiou A; Palmieri D; Tsatsanis C; Alaimo S; Sehgal L; Carbone DP; Coppola V; Tsichlis PN
Nat Commun; 2021 Jul; 12(1):4624. PubMed ID: 34330897
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
14. Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells.
Griesing S; Kajino T; Tai MC; Liu Z; Nakatochi M; Shimada Y; Suzuki M; Takahashi T
Cancer Sci; 2017 Jul; 108(7):1394-1404. PubMed ID: 28474808
[TBL] [Abstract][Full Text] [Related]
15. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer.
Escobar-Hoyos LF; Penson A; Kannan R; Cho H; Pan CH; Singh RK; Apken LH; Hobbs GA; Luo R; Lecomte N; Babu S; Pan FC; Alonso-Curbelo D; Morris JP; Askan G; Grbovic-Huezo O; Ogrodowski P; Bermeo J; Saglimbeni J; Cruz CD; Ho YJ; Lawrence SA; Melchor JP; Goda GA; Bai K; Pastore A; Hogg SJ; Raghavan S; Bailey P; Chang DK; Biankin A; Shroyer KR; Wolpin BM; Aguirre AJ; Ventura A; Taylor B; Der CJ; Dominguez D; Kümmel D; Oeckinghaus A; Lowe SW; Bradley RK; Abdel-Wahab O; Leach SD
Cancer Cell; 2020 Aug; 38(2):198-211.e8. PubMed ID: 32559497
[TBL] [Abstract][Full Text] [Related]
16. KRAS phosphorylation regulates cell polarization and tumorigenic properties in colorectal cancer.
Cabot D; Brun S; Paco N; Ginesta MM; Gendrau-Sanclemente N; Abuasaker B; Ruiz-Fariña T; Barceló C; Cuatrecasas M; Bosch M; Rentero C; Pons G; Estanyol JM; Capellà G; Jaumot M; Agell N
Oncogene; 2021 Sep; 40(38):5730-5740. PubMed ID: 34333552
[TBL] [Abstract][Full Text] [Related]
17. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
[TBL] [Abstract][Full Text] [Related]
18. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
Kim JY; Welsh EA; Fang B; Bai Y; Kinose F; Eschrich SA; Koomen JM; Haura EB
Mol Cancer Res; 2016 Oct; 14(10):1019-1029. PubMed ID: 27422710
[TBL] [Abstract][Full Text] [Related]
19. Small molecule amiloride modulates oncogenic RNA alternative splicing to devitalize human cancer cells.
Chang JG; Yang DM; Chang WH; Chow LP; Chan WL; Lin HH; Huang HD; Chang YS; Hung CH; Yang WK
PLoS One; 2011; 6(6):e18643. PubMed ID: 21694768
[TBL] [Abstract][Full Text] [Related]
20. Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell Survival.
Fei DL; Motowski H; Chatrikhi R; Prasad S; Yu J; Gao S; Kielkopf CL; Bradley RK; Varmus H
PLoS Genet; 2016 Oct; 12(10):e1006384. PubMed ID: 27776121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]